Thursday 11 June 2020

The Brewery, London EC1


2011 Voting Panel


Ian Restall

Flathill Communications plc
Voting Panel Chairman

Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and since founding The Design Portfolio in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also President of The Design Portfolio Inc. and a member of the Investor Relations Society.


Will Brooks

Will Brooks recently joined Tranziger as an Investment Partner. Prior to this, he managed the Private Equity and quoted portfolio’s of life sciences investments for the fund Quest for Growth and has acted as an observer or director within invested companies. He achieved this in his role as Investment Director at Quest Management, an independent asset management company based in Belgium. It manages both private and public equity investments in European life sciences and technology companies. Examples of investee companies included Tannox (US), Crucell and Kiadis (NL Wilex, Trigen and IDEA (D)), Cyclacel, Plethora, Fura Medical, Prosonix and Sphere Medical (UK). 

Will’s unique combination of technical and business skills to manage both the Private Equity and quoted portfolio of life sciences investments derives from over 20 years spent in the Biotechnology industry. His experience covered active clinical and development management within the industry.  He was Head of product development at Antisoma PLC and has provided strategic and board level consulting for leading companies and consultancies, advising on issues such as clinical development, technology assessment, business development, financial strategy and licensing.  Will has acted as an advisor to both the European Commission and the Scottish Government.  He is a frequent speaker at healthcare conferences and is a member of the European Mediscience Awards Voting Panel.



Mark Court

Buchanan Communications

At Buchanan, Mark advises a wide range of healthcare clients on their communication requirements. He joined Buchanan in 2003 after a successful career in journalism on titles including The Times, where he was Health Industries Correspondent, the Sunday Telegraph, Daily Mail and Investors Chronicle.  A science graduate of London University, Mark also holds a diploma from the London College of Communication.


Mary Jane Elliott


Mary-Jane leads the Healthcare team at M:Communications.  She has more than 13 years of healthcare sector experience.  Prior to joining M: Mary-Jane was a Partner at Buchanan Communications where she spent six years advising healthcare clients.  Previously Mary-Jane worked at the FTSE 250 company PowderJect Pharmaceuticals where she began her career as a scientist and then joined the Corporate Communications and Investor Relations team.  She has advised both public and private companies in the UK and internationally, across all sub-sectors of healthcare, and has a broad range of experience including work on various M&A situations, over 20 international IPOs and over ten secondary fundraisings.  As a healthcare specialist, Mary-Jane has a BSc (Hons) in BioMedical Sciences.



Emma Palmer Foster

EJ Palmer Consulting

Emma Palmer Foster is a consultant with almost 20 years’ experience in the European pharmaceutical and biotechnology sector, via investment banking, financial communications, investor relations, journalism and technology transfer. Exploiting a gap in the strategic consultancy services available to pharmaceutical and biotechnology companies in Europe, Emma established EJ Palmer Consulting in 2007. EJPC advises companies on corporate and financial strategy, IR and communications and works with clients in a range of areas, including Board roles.

Emma has an MA in Biochemistry from the University of Oxford and an MBA from the University of Durham. She is a Trustee of the mental health charity MPF Counselling, a Visiting Fellow at Durham Business School, a member of the UK Investor Relations Society (holding its Certificate in IR) and an Associate Member of the Chartered Institute of Public Relations.



Emma Garland

Design Portfolio

Emma is Head of Client Services at Design Portfolio . She is a highly organised and customer focused account director with much experience in the corporate reporting field, having worked on numerous annual, interim and CR report projects, analyst presentations and other investor relations material. Emma also takes an active role in monitoring regulatory and best practice information and is a member of the Investor Relations Society.


Steve Cox


Steve joined Matrix in 2009 from Elixir Securities where he was founder and CEO. Prior to Matrix, Steve spent nine years as a pharmaceutical/biotech analyst, most latterly as Head of Biotech & Healthcare Research at Commerzbank Securities. Steve also worked in the top-ranked biotech research  team at UBS, where he was instrumental in Serono’s $2bn secondary financing and Genmab’s $230m IPO. Prior to UBS, Steve held positions in research within the number one ranked pharmaceuticals team at HSBC and at Cazenove where he was responsible for 16 IPOs raising over $640m in total for companies including Cambridge Antibody Technologies and Celltech. Steve also has industry experience having spent five years in research and corporate development for Genzyme Corp in the US. Steve has a Degree in Applied Chemistry from University of Hertfordshire and an MBA (Finance) from Cass Business School.



Stefan Hamill

Peel Hunt

Stefan joined Peel Hunt in January 2011, joining forces with Paul Cuddon to form what we believe is the strongest team in UK healthcare and life sciences. Prior to joining Peel Hunt, Stefan was a founder of independent research house Clear Capital (now part of Espirito Santo) where he covered a wide variety of firms across the sector and was ranked number three in Extel. Stefan was formerly a strategy consultant and has a PhD in antibody engineering from the University of Cambridge.


Anthony Hartley

Morgan Stanley

Dr Anthony Hartley is an Executive Director in the Healthcare Investment Banking Group at Morgan Stanley, where he focuses on pharmaceutical and biotechnology companies on a pan-European basis.

Anthony has spent over ten years in healthcare investment banking, predominantly focused on the European biotech and pharmaceutical sectors, and has completed and advised on numerous M&A and corporate finance transactions in both the public and private biotech sectors. Before joining Morgan Stanley, Anthony previously worked for Lehman Brothers Europe and Credit Suisse First Boston.

Anthony holds a Doctorate (D.Phil) in Pharmacology from the University of Oxford and an MBA (Distinction) from Manchester Business School.  Prior to his career in investment banking, Anthony spent a total of seven years in the pharmaceutical industry working in a variety of research and commercial roles at Pfizer, GlaxoSmithkline and AstraZeneca.



Stephen McGarry

Clear River Capital


Joep Muijrers

Life Sciences Partners

Joep joined LSP as a Partner in the Amsterdam office in early 2007. A substantial part of Joep’s activities are dedicated towards LSP’s public franchise, which he helped establish and manage since its inception.

Prior to joining LSP, he held the position of Director Corporate Finance and Capital Markets at Fortis Investment Banking, where he played a key role in the origination and execution of numerous financial and strategic transactions for biotech companies located in Europe as well as in the US. He also held the position of Managing Director of BioMedbooster, a technology transfer company active in the field of life sciences.

Joep received his PhD in Molecular Biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg and he holds an MSc degree in biochemistry from the University of Nijmegen.



Nick Rodgers

IPSO Ventures plc

Nick is the CEO of technology commercialisation business IPSO Ventures and the founder of the Mediscience Awards dinner. Nick is an accountant and former investment banker with Beeson Gregory (later Evolution Securities). Nick is also the Chairman of Oxford BioMedica plc and a Non-executive Director of TMO Renewables Limited and Morvus Technology Limited.


Melanie Toyne-Sewell

College Hill Life Sciences

Melanie is a specialist in financial and corporate communications for Life Science companies and heads up Financial PR for the Life Sciences team. Prior to College Hill, Melanie was Head of Healthcare at the Hogarth Partnership, a partner in the Financial Dynamics Life Sciences team and a Director of Merlin Financial. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare sectors. Before entering the field of financial PR, Melanie was at Price Waterhouse where she qualified as a chartered accountant. She has a BA Hons in Biochemistry from Oxford University.